Over the past year, access to innovative therapies and diagnostic solutions in Poland has increased by 5 points and stands at 58 points out of 100 on the KPI scale, according to the latest data collected by the Access GAP platform, which presents data on the Visegrad Group countries. The Czech Republic remains the leader, followed by Slovakia, with Poland in third place, slightly ahead of Hungary. The Association of Employers of Innovative Pharmaceutical Companies INFARMA presented the report, which consists of a comparison of the Visegrad Group countries and the Polish Refund Radar, on Wednesday.
The data is clear: access to innovative drugs and diagnostic solutions is improving in all Visegrad countries, and in Poland it has improved by 16 points over three years. In the first edition, presented in 2022 (data for 2021), the overall Access GAP index for Poland was ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
